/
CING
$5.32+$0.36 (+7.26%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$66.8M
13M shares
52-week range
$3.16 – $11.89
25% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
9.25%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1062.68
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $178.9K | $842.4K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$178.9K | −$842.4K | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $9.1M | $5.1M | $8.4M | $9.0M | $15.5M | $9.4M | $9.8M |
| Operating income | −$11.6M | −$7.1M | −$20.7M | −$17.5M | −$22.8M | −$15.6M | −$19.9M |
| EBITDA | −$11.5M | −$6.2M | −$20.0M | −$17.1M | −$22.2M | −$15.0M | −$19.4M |
| Net income | −$11.5M | −$7.2M | −$20.7M | −$17.7M | −$23.5M | −$16.6M | −$22.4M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -242.89 | -12.70 | -55.80 | -31.20 | -311.99 | -10.20 | -4.13 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-2.42 | $-2.87–$-1.83 | 5 |
| 2027 | $17M | $-1.20 | $-2.53–$2.12 | 5 |
| 2028 | $20M | $-1.13 | $-1.20–$-1.06 | 2 |
| 2029 | $44M | $0.29 | $0.04–$1.07 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.05
Price
$5.32
Implied downside
-99%
Peer comparison
Cingulate Inc. Common Stock
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
www.cingulate.com- Employees
- 14
- IPO / List date
- Dec 8, 2021
- HQ
- KANSAS CITY, KS
Held by traders on TradeandTell
No one on the platform currently holds CING.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 31,888 | $198.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-08-09 | 1-for-12reverse |
| 2023-11-30 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded CING yet.
